Business Wire

Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on sevasemten, an ...
Business Wire

Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 29th International Annual ...
Morningstar

Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society

Craig McDonald, M.D., Professor and Chair, Department of Physical Medicine & Rehabilitation, Professor of Pediatrics, Director MDA Neuromuscular Disease Clinics ...
Seeking Alpha

Edgewise: Remains A Buy After Latest Becker Muscular Dystrophy Data

Edgewise Therapeutics (EWTX) is building itself up as a good long-term biotech to hang onto. Especially, when you consider that it was able to report positive results from its phase 2 CANYON study, ...
WebMD

Becker Muscular Dystrophy: What You Need to Know

Becker muscular dystrophy (BMD) is a type of muscular dystrophy, a genetic condition that weakens and damages muscles. It can worsen with age. However, its symptoms are less severe than those of ...
Nasdaq

Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference

– Company to host an Industry Forum to discuss the lived experience of Becker and clinical advancements featuring a leading neuromuscular disease expert and a patient advocate – Edgewise is sponsoring ...